Industry Update

    loading  Checking for direct PDF access through Ovid


September 2014, the period covered by this article, was characterized by continued prospective and actual acquisition activity and some big possible deals such as Valeant and Allergan, were still in prospect. A number of drug approvals for medicines with novel therapeutic targets such as anti-PD-1 for oncology or employing delivery technologies such as corticosteroid intravitreal implants for diabetic macular edema were announced during the month.

Related Topics

    loading  Loading Related Articles